Biopharma CRO industry in China: landscape and opportunities

Drug Discovery Today

Volumn 20, Issue 7, 2015, Pages 794-798

  Xia, Christine ^a   Gautam, Ajay ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT;

ANIMAL MODEL; ARTICLE; BIOMEDICINE; CHINA; CLINICAL PHARMACOLOGY; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; FUTUROLOGY; GOVERNMENT; HUMAN; MERGERS AND ACQUISITIONS; NONHUMAN; POLICY; PRODUCTIVITY; RISK MANAGEMENT; TOXICOLOGY; COMMERCIAL PHENOMENA; COOPERATION; ECONOMICS; FINANCIAL MANAGEMENT; INTERDISCIPLINARY COMMUNICATION; NONBIOLOGICAL MODEL; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PUBLIC RELATIONS; TRENDS;

CHINA; COMMERCE; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERINSTITUTIONAL RELATIONS; MODELS, ORGANIZATIONAL; ORGANIZATIONAL OBJECTIVES; OUTSOURCED SERVICES; RISK SHARING, FINANCIAL;

EID: 84936845725     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.02.007     Document Type: Short Survey

References (4)

1. A. Gautam, and S. Yang A framework for biomedical innovation in emerging markets Nat. Rev. Drug Discov. 13 2014 646 647
2. S. Goodall The promise of the East: India and China as R&D options Nat. Biotechnol. 24 2006 1061 1064
3. I. Khanna Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discov. Today 17 2012 1088 1102
4. S.P. Forster Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development Drug Discov. Today 19 2014 348 355